If you are not happy with the results below please do another search
Authors: Joshua D. Brown, Almut G. Winterstein
Journal of Clinical Medicine, 8 July 2019
—
Cannabidiol (CBD) is ubiquitous in state-based medical cannabis programs and consumer products for complementary health or recreational use. CBD has intrinsic pharmacologic effects and associated adverse drug events (ADEs) along with the potential for pharmacokinetic and pharm…
Answers from SCC Members to an inquiry on the safety of using CBD when patients are taking medications metabolized by the P450 system.
Authors: Rafael G. dos Santos, Francisco S. Guimarães, José Alexandre S. Crippa, et al
Expert Opinion on Drug Metabolism & Toxicology, 9 April 2020
—
Introduction: Recent trials using cannabidiol (CBD) have shown that most acute and prolonged adverse effects of CBD are mild to moderate, with rare serious adverse effects (SAEs). This review focused on analyzing SAEs of CBD and their possible relation to drug-drug interaction…
Authors: Alexandra L. Geffrey, Sarah F. Pollack, Patricia L. Bruno, Elizabeth A. Thiele
Epilepsia, August 2015
—
OBJECTIVE: Under an expanded access investigational new drug (IND) trial, cannabidiol (CBD) is being studied as a possible adjuvant treatment of refractory epilepsy in children. Of the 25 subjects in the trial, 13 were being treated with clobazam (CLB). Because CLB and CBD are…
Authors: Antonio Waldo Zuardi
Brazilian Journal of Psychiatry, September 2008
—
OBJECTIVE: The aim of this review is to describe the historical development of research on cannabidiol. METHOD: This review was carried out on reports drawn from Medline, Web of Science and SciELO. DISCUSSION: After the elucidation of the chemical structure of cannabidiol in 1…
To summarize and evaluate clinical experiences with refractory status epilepticus in which cannabidiol (CBD) was utilized for cessation of seizure activity. A comprehensive literature review was performed on PubMED, MEDLINE, Scopus, and CINAHL between May – June 2022 with the assistance of a medical reference librarian using the following search terms: “Cannabidiol” [MAJR], “Status Epilepticus” [MAJR], “New-Onset Refractory Status Epilepticus”, and “cannabidiol.” Reports that provided dosing regimens and patient outcomes were included.
The management of behavioral symptoms and rigidity in patients with dementia constitutes a significant challenge. Short-term studies suggest an interest in the use of medical cannabis, but long-term data are lacking. The objective of this study was to investigate the feasibility and long-term safety of administering tetrahydrocannabinol/cannabidiol (THC/CBD) treatment as an additional drug to a poly medicated population with severe dementia, evaluate clinical improvements, and collect information on the pharmacokinetics of cannabinoids and possible drug–drug interactions.
Explore the different types of plant synergy, herbs that may combine well with cannabis, and the healing properties of botanicals that science will never be able to fully explain.
In an effort to set the record straight on the questionable conclusions presented in a recent cannabis and heart attack risk study, SCC Board Members Sherry Yafai, MD and Patricia C. Frye, MD weigh in with their observations and research evidence.
The Society of Cannabis Clinicians interviews mothers of children with autism about their journey and how cannabis has played a role.
Dr. Yesid Ramirez created a free, day-long intensive program on cannabis science at ICESI University in Cali, Colombia for historically discriminated indigenous groups.
Cannabidiol (CBD), the main nonpsychoactive constituent of Cannabis sativa, has shown a wide range of therapeutically promising pharmacological effects either as a sole drug or in combination with other drugs in adjunctive therapy. However, the targets involved in the therapeutic effects of CBD appear to be elusive.
Connect with healthcare professionals around the globe to get the most up-to-date medical cannabis information.
The curriculum brings hands-on practical guidance on how to develop personalized treatment regimens and more.
Join our email list for access to the latest clinical research and discounts on emerging cannabinoid education
